ORA Master Agreement for Services has been completed. The agreement is for the use of OMRF Scientific Core Facility Services such as Biacore, Clinical Genomics Center, Imaging Core Facility, DNA Sequencing and Flow Cytometry. When using these services it is not usually required to use an Independent Contractor Agreement for services. Please find a copy of the agreement attached.
VPR Staff Editor
Kathy Kyler is the staff editor for the OUHSC campus. Her assistance is available on request without charge through the office of the Vice President for Research. You can contact her by e-mail at Kathy-Kyler@ouhsc.edu or by calling ORA at 271-2090. Please allow sufficient time for review. In general, turnaround time is 7 business days for manuscripts and 5 business days for grant proposals of 12 pages or less for the research plan.
RETURN TO RESEARCH – PLAN FOR PHASE TWO REOPENING OF RESEARCH AT OUHSC
The return to full, normal operations of research will continue to be a gradual, phased process. In accordance with the OUHSC COVID-19 Return Plan the OUHSC Vice President for Research (VPR) is announcing the Return to Research – Plan for Phase Two Reopening of Research at OUHSC.
Human Subjects Research
The Phase One Plan for Reopening of Human Subjects Research (effective May 11, 2020) will remain in place with no change. The information detailing this plan can be found at: https://compliance.ouhsc.edu/HRPP/COVID-19-Information
Bench Laboratory Research
Starting August 10, 2020 the Phase Two Plan for Reopening of Bench Laboratory Research will become effective. The information detailing this plan can be found at: Phase Two Plan for Reopening of Bench Laboratory Research at OUHSC.
Oklahoma Center for Stem Cell Research (OCASCR) – Research, Education/Travel and Equipment Grants
Deadline September 15, 2020.
The Stephenson Cancer Center is pleased to announce the American Cancer Society – Institutional Research Grant (ACS-IRG) Pilot Project grant funded by the American Cancer Society. The ACS-IRG is a unique source of funding entrusted to SCC that provides seed money for young investigators interested in cancer-related research. While the grant is administered at SCC, eligible applicants at OUHSC Tulsa, OU Norman and OU-Tulsa may apply.
Applicants may request up to $50,000 for a 12-month project that:
- Is relevant to the goals of the ACS and is cancer-related
- Has high scientific merit
- Has potential to be leveraged for future extramural funding
Only full time Assistant Professors within six years of their initial faculty appointment and with no active peer-reviewed funding from national funding agencies (e.g. NIH, DOD, NSF, ACS) may apply. Applications must be received by the Office of Cancer Research (firstname.lastname@example.org) by 5 PM, September 8th, 2020. Application guidelines and application packet are attached. Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the Office of Cancer Research staff at email@example.com or call 405-271-1878.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system related to COVID-19 please include “COVID-19” in the title so that we are able to search on it later.
Notice to Extend Eligibility for Submission of NIAID K99 /R00 Pathway to Independence Award Applications (and Physician-Scientist K99/R00) due to COVID related Disruptions (NOT-AI-20-068)
Notice of Informational Webinar on PAR-20-213: National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant (T32 - Clinical Trial Not Allowed)
Notice of Pre-Application Webinars for the NHGRI Genomic Innovator Award (NOT-HG-20-053)
Notice of Pre-Application Webinars for the Impact of Genomic Variation on Function (IGVF) Consortium FOAs (RFA-HG-20-043, RFA-HG-20-044, RFA-HG-20-045, RFA-HG-20-046, RFA-HG-20-047) (NOT-HG-20-055)
Request for Information (RFI): Information and Data Resources Needed by the Health Services Research Community for Research and Practice. (NOT-LM-20-017)
Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-064: Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) (NOT-AA-20-020)
Notice of Change to RFA-AG-21-003 New/Unconventional Animal Models of Alzheimer’s Disease (R24 Clinical Trial Not Allowed) (NOT-AG-20-047)
Notice of Temporary Extension of Eligibility for the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) (NOT-DE-20-031)
Notice of Revision to Funding Opportunity Description for RFA-DK-20-017: Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium – Field Epidemiology Sites (U01 - Clinical Trial Not Allowed) (NOT-DK-20-041)
Notice of Revision to Funding Opportunity Description for RFA-DK-20-018, Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium Renal Science Core (U01 - Clinical Trial Not Allowed)(NOT-DK-20-042)
Notice of Revision to Funding Opportunity Description for RFA-DK-20-019, Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Scientific Data Coordinating Center (U24 Clinical Trial Not Allowed) (NOT-DK-20-043)
Notice of NHLBI Participation in PAR-18-901 "Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)" (NOT-HL-20-807)
Notice of NHLBI Participation in PAR-19-098 "Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)" (NOT-HL-20-808)
Notice of Change in Application Due Date for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)" (NOT-HL-20-811)
Notice of NLM Participation in PAR-20-150 "NIMHD Exploratory/Developmental Research Grant Program
(R21 - Clinical Trial Optional)" (NOT-LM-20-016)
Notice of NIMHD Withdrawal from Participation in PA-20-195 and PA-20-196: NIH Exploratory/Developmental Research Grant Programs (Parent R21 Clinical Trial Not Allowed) and (Parent R21 Basic Experimental Studies with Humans Required) (NOT-MD-20-027)
Notice of Change to Key Dates for RFA-NS-18-021 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Required)"
Notice of Change to Key Dates for RFA-NS-18-022 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required)"
Notice of Change to Key Dates for RFA-NS-18-023 "BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Required)" (NOT-NS-20-105)
Notice of Participation in RFA-OD-20-023, "Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)" (NOT-TR-20-034)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed) (NOT-CA-20-095)
Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Consortium on Co-managing Chronic Pain and Opioid Use Disorder (C3PO) (RM1) (NOT-DA-20-071)
Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Research on Related DSM-5 Diagnoses (R2D2) Coordination and Dissemination Center (NOT-DA-20-077)
Notice of Intent to Publish Funding Opportunity Announcements for Music and Health: Understanding And Developing Music Medicine (R01) (NOT-NS-20-096)
Notice of Intent to Publish a Funding Opportunity Announcement for Music and Health: Understanding And Developing Music Medicine (R21) (NOT-NS-20-100)
Notice of Special Interest: Alcohol and Aging (NOT-AA-20-019)
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases (NOT-DK-20-040)
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least two months prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support (PA-20-074) - Deadline January 25, 2021
Research to Improve Native American Health (R21 Clinical Trials Optional) (PAR-20-214) Deadline May 17, 2021 and May 17, 2022
Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
Deadline May 17, 2021 and May 17, 2022
NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed)
(PAR-20-283) - Deadline October 23, 2020 and October 22, 2021
Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed) (RFA-CA-20-044)- Deadline October 30, 2020
NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional) (RFA-HD-21-023) Deadline March 31, 2021